Trials / Completed
CompletedNCT04495283
A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy
A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination of Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Nevakar, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy
Detailed description
A Phase 2, Randomized, Double-Blind, Placebo- and Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Combination Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy Up to 80 subjects will be randomized (32 in each active treatment group, 16 placebo). To evaluate the efficacy of combination pregabalin (PGB) and acetaminophen (APAP) administered vs. placebo for pain control in subjects undergoing bunionectomy. The placebo will be the saline solution.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties. |
| DRUG | Acetaminophen | Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent. |
| OTHER | Placebo 1 | Placebo for APAP |
| OTHER | Placebo 2 | Placebo for combination |
Timeline
- Start date
- 2020-07-28
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
- First posted
- 2020-07-31
- Last updated
- 2021-11-23
- Results posted
- 2021-11-23
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04495283. Inclusion in this directory is not an endorsement.